Search 

MP Healthcare Ventures is the corporate venture arm of Mitsubishi Tanabe Pharma founded in 2006 and based in Boston Massachusetts. The firm is looking to provide equity capital to seed and venture stage companies in the life science space. The firm is looking to provide companies with $5 million over the lifetime of the investment and plans on making 2-3 investments over the next year. The firm will invest in companies located anywhere around the world.

MyeloRx is a northern California based biotechnology company. Our lead compound, MRx102, is a small molecule inhibitor of RNA polymerase II. Molecules related to MRx102 have shown clinical efficacy in AML patients in Europe and China.  MRx102 is covered by issued composition of matter patents in the U.S., E.U., China and Japan.  While AML is the initial indication, MRx102 has also been found active in stringent models of pancreatic and lung cancer. Our collaborators include clinical oncologists from MD Anderson Cancer Center, JHU School of Medicine and City of Hope Medical Center. R&D activities have been funded primarily by a $2M NCI SBIR contract. Our strong scientific and management team is lead by Dr. John Musser; it has brought multiple products to market. We are seeking funding to complete an IND which is projected to take less than a year based on the extensive studies completed to date (manufacturing, formulation, toxicology/ PK in rats and dogs etc.)  and a Phase 1 clinical trial in AML patients.

Novelogics Biotechnology Inc. has developed unique next generation antibody immunotherapies for treating multiple types of advanced cancers including colon and prostate cancers.  Immunotherapies for cancer are anticipated to be a $35B per year industry in the upcoming years.  

Cancer Drugs with Safety in Mind

From the beginning the novel and specific design of the therapeutic antibody drug minimizes the potential for autoimmune diseases or harming good cells with the bad.  We are dedicated to making cancer treatments that won't make you sick to get you better.

Unecumbered, Founder Owned

Novelogics has developed their assets in an unecumbered envriornment allowing investors to work directly with the team.  At this time the companyis 100% founder owned and undiluted.  Novelogics is anticipating an early exit and has begun discussions with pharmaceutical companies interested in this area.

In addition; a related Medical Device

In addition to the drug, Novelogics has a second PCT Patent pending for a related medical device with a readily available "go to" market in place. 

NuvOx Pharma is developing a series of biologics that increase tissue oxygenation. The company's first market will be in oncology, where increased tumor oxygenation increases the response of tumors to radiation therapy. The company recently started a Phase 1b clinical trial in Glioblastoma Multiforme, and is raising a $2.5 million Series A to complete this trial. Afterwards it will seek partners for a Phase 2b in Glioblastoma, and Phase 1b trials in lung cancer and other oncology indications. After growing to a critical mass in oncology, the company will seek to become standard treatment to increase tissue oxygenation for patients suffering from heart attack, stroke, hemorrhaggic shock, and traumatic brain injury.

The NYU Office of Industrial Liaison (OIL) promotes the commercial development of NYU technologies into products to benefit the public, while providing resources to the University to support its research, education, and patient care missions. NYU OIL also facilitates research collaborations between NYU researchers and industry on projects of mutual interest.

In 2013, NYU launched the Office of Therapeutics Alliances (OTA). OTA is a nimble, "virtual biotech" approach to advance novel therapeutic projects by playing on the strengths of NYU in dissecting disease pathways and those of external, professional capabilities in early stage R&D. OTA identifies NYU projects with potential for addressing unmet needs, delineates the path to therapeutic proof of concept and assembles internal and external resources tailored to each specific project’s needs to maximize the likelihood of successful partnerships with biopharma, new biotech startups or disease foundations. 

O2h has a track record of investing in emerging biotech, small molecule and frontier life science starts-ups

A passion for entrepreneurship and life sciences motivates o2h to participate in syndicated seed stage investments. O2h are ready to support the investments with active or passive support to further the objectives of the company.

Orphagen’s focus is small molecule discovery at novel drug targets. We create programs leading to first-in-class drugs. Our goal is to partner these with development stage pharmaceutical companies.

We have been first mover in creating three discovery programs for novel targets, including one program that initiated Phase 1 clinical trials with a strategic partner (JT Pharma) in 2013 for autoimmune disease.

We work with novel drug targets from a very productive target class, the nuclear receptors.

Our work has so far been funded by $15 M in federal grants and partnership revenue. Orphagen is in the process of raising equity funding to accelerate current programs.

Orphagen’s lead internal program is for retinitis pigmentosa, the major form of hereditary blindness. Closely following are antagonists to SF-1, a promising target for treatment of Cushing’s syndrome, a life-threatening endocrine disorder, and two cancers with an endocrine connection: prostate cancer and adrenocortical cancer. New target screening may lead to first-in-class programs for glioblastoma, sickle cell anemia, and cancer immunotherapy.